The US federal government has cleared the proposed sale of California-based Complete Genomics to China's BGI-Shenzen, The New York Times reports. The acquisition was given the OK by Committee on Foreign Investment in the United States, which examines the national security ramification of sales of US companies to foreign buyers. The Times adds that the Federal Trade Commission still needs to green-light the deal on antitrust grounds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in PNAS

Different Approach

All of It

The Foods You Eat

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.